文献速递腹部MR

钆贝葡胺增强MRI肝细胞期定量参数可预测肝细胞癌患者肝切除术后肝衰竭及总生存

Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
PubMed 文献 · Eur J Radiol · 2022-07-22

这项多中心回顾性研究纳入307例接受钆贝葡胺增强MRI的肝细胞癌患者,测量肝细胞期肝-门静脉对比比(LPC)和肝-脾对比比(LSC),发现两者均为肝切除术后肝衰竭的独立危险因素(LPC的AUC 0.882,LSC的AUC 0.782,LPC预测效能优于LSC),且LPC>1.07或LSC>0.89者5年总生存率更高。

要点

  • 肝细胞期LPC和LSC是肝切除术后肝衰竭的独立危险因素,LPC预测效能优于LSC(AUC 0.882 vs 0.782)。
  • LPC和LSC亦为总生存的显著预后因素,LPC>1.07或LSC>0.89者5年总生存率更高。
  • LPC和LSC的截断值分别为1.07和0.89。

核心结论

  • 钆贝葡胺增强MRI肝细胞期获得的定量参数是预测肝细胞癌患者肝切除术后肝衰竭和总生存的有效影像生物标志物。

研究设计与样本

  • 多中心回顾性研究,纳入307例接受钆贝葡胺增强MRI的肝细胞癌患者,测量肝细胞期LPC和LSC,采用逻辑回归分析肝切除术后肝衰竭危险因素,ROC曲线评估预测效能,Cox比例风险回归确定总生存预后因素。

诊断标准与关键数值

  • 肝切除术后肝衰竭发生于69例(22.5%);LPC和LSC预测肝切除术后肝衰竭的AUC分别为0.882和0.782,LPC预测效能优于LSC;LPC和LSC的截断值分别为1.07和0.89;LPC>1.07或LSC>0.89者5年总生存率高于LPC≤1.07或LSC≤0.89者。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the value of the quantitative parameters obtained from gadobenate dimeglumine-enhanced magnetic resonance imaging (MRI) at the hepatobiliary phase for predicting post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.

METHOD: This multicenter retrospective study included 307 patients who underwent gadobenate dimeglumine-enhanced MRI. The quantitative liver-to-portal vein contrast ratio (LPC) and liver-spleen contrast ratio (LSC) at the hepatobiliary phase were measured. Logistic regression analyses were used to evaluate risk factors for post-hepatectomy liver failure. The capacity of the LPC and LSC to predict post-hepatectomy liver failure was evaluated via receiver operating characteristic (ROC) curve. The Cox proportional hazards regression was used to identify prognostic factors for overall survival (OS).

RESULTS: Post-hepatectomy liver failure was observed in 69 patients (22.5%). The LPC and LSC were independent risk factors for the development of post-hepatectomy liver failure, and the areas under the ROC curves of LPC and LSC were 0.882 and 0.782, respectively. The predictive performance of LPC for post-hepatectomy liver failure was superior to LSC. The LPC and LSC were also significant prognostic factors for OS. The cut-off values for the LPC and LSC were 1.07 and 0.89, respectively. The 5-year OS rate was higher in patients with LPC > 1.07 or LSC > 0.89 than in patients with LPC ≤ 1.07 or LSC ≤ 0.89.

CONCLUSIONS: The quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase were effective imaging biomarkers for predicting both post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Cai, Lin, Sun, et al. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma. Eur J Radiol. 2022. PMID: 35901599. doi:10.1016/j.ejrad.2022.110449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。